Cargando…
Identification of GRIN2D as a novel therapeutic target in pancreatic ductal adenocarcinoma
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease with a dismal prognosis, and despite significant advances in our understanding of its genetic drivers, like KRAS, TP53, CDKN2A, and SMAD4, effective therapies remain limited. Here, we identified a new therapeutic target GRI...
Autores principales: | Wang, Jiatong, Wong, Chi Hin, Zhu, Yinxin, Yao, Xiaoqiang, Ng, Kelvin K C, Zhou, Chengzhi, To, Ka Fai, Chen, Yangchao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10410818/ https://www.ncbi.nlm.nih.gov/pubmed/37553583 http://dx.doi.org/10.1186/s40364-023-00514-4 |
Ejemplares similares
-
LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma
por: Zhu, Yin-Xin, et al.
Publicado: (2020) -
Therapeutic Targeting of Autophagy in Pancreatic Ductal Adenocarcinoma
por: Raufi, Alexander G., et al.
Publicado: (2021) -
The establishment of CDK9/RNA PolII/H3K4me3/DNA methylation feedback promotes HOTAIR expression by RNA elongation enhancement in cancer
por: Wong, Chi Hin, et al.
Publicado: (2022) -
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
por: Thakur, Gitika, et al.
Publicado: (2021) -
Hydrogel-Based Therapeutics for Pancreatic Ductal Adenocarcinoma Treatment
por: Liu, Jinlu, et al.
Publicado: (2023)